PeptidePedia The community reference

Purity claim inflation (revision 15)

Old revision·04:41, 28 Mar 2025·ForgeryFinder

This is an old revision of this page, as it stood at 04:41, 28 Mar 2025, saved by ForgeryFinder with the summary expand §Reading against inflation. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Purity claim inflationQuality failure
<9090919293949596979899+reportsreported HPLC area% across community-submitted reports
The same material can be described by several defensible numbers, and the largest is usually chosen.
Distinguished fromForgery — the figure here is genuine
MechanismMethod choice, integration, and framing
Topic infobox · conventions

Purity claim inflation is the presentation of a purity figure in a manner that overstates what it establishes. Unlike forgery, the figure is generally genuine: what is misleading is the method that produced it, the way it was integrated, or the framing that presents it as answering a question it does not answer.[1]

The most consequential form is the substitution of purity for content. An area percent figure is normalised: it describes the proportion of detected material attributable to the main peak, and it is unaffected by how much peptide is present. A vial can be 99% pure and contain half the stated mass. Presenting purity where content is the relevant question is the commonest inflation of all.[1]

Because these practices operate through selection rather than fabrication, they are not detectable by asking whether a report is genuine. They are detectable, if at all, by reading what the report actually measured.

Mechanisms

[edit]
MechanismEffect on the number
Short gradientClose-eluting impurities merge into the main peak
Generous integration boundariesShoulders counted as main peak
Detection wavelength chosen for the analyteImpurities absorbing elsewhere under-detected
Reporting purity in place of contentSilence on how much peptide is present
Quoting the best of several determinationsSelection from a distribution
Aggregating related substances into one figureIndividual impurities concealed

None of these is necessarily improper. A short gradient may be entirely appropriate for a well-characterised material; aggregate reporting of related substances is standard in some contexts. What makes a presentation inflationary is the gap between what the method establishes and what the figure is used to assert.[2]

The detection-wavelength point is the least appreciated. Peptide purity is usually determined at 214 nm, where the amide bond absorbs, so response is roughly proportional to the number of bonds and impurities are detected reasonably. A determination at 280 nm, where aromatic side chains absorb, will systematically under-detect impurities lacking those residues. Both are legitimate methods; they do not answer the same question.

What a purity figure does establish

[edit]

An area percent purity figure establishes that, of the material detected by that detector under those conditions, the stated proportion eluted as the main peak. That is a real and useful fact and this article should not be read as dismissing it.[1]

What it does not establish: how much peptide is in the vial; that the main peak is the intended molecule; that undetected species are absent; that the figure would be reproduced on a different method.

A complete characterisation therefore requires, at minimum, identity by mass, purity by a specified chromatographic method, content, and water. Certificates supplying all four are a minority in submissions to this wiki, though all four are ordinary components of a specification where one exists.[3] A certificate supplying only the second is not thereby dishonest — but a claim about how much active substance a vial contains cannot rest on it.[4]

See also

References

  1. ^ a b c United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
  2. ^ United States Pharmacopeia, General Chapter <621>, Chromatography.
  3. ^ International Council for Harmonisation, Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (1999).
  4. ^ PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see Project:Sourcing guidelines).